Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Pain and Stress Management for Fibromyalgia

15. März 2016 aktualisiert von: Mark A. Lumley, Wayne State University

Emotional Exposure and Cognitive Behavioral Therapies for Fibromyalgia

This interventional, randomized controlled study seeks to test the effects of an innovative emotional exposure and processing treatment that targets stress resolution, by comparing it with cognitive-behavioral therapy and a Fibromyalgia education comparison condition. The investigators also will test proposed mediators of the intervention, including improved autonomic regulation, and explore which subgroups of patients benefit the most from each approach.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

230

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Vereinigte Staaten
    • Michigan
      • Ann Arbor, Michigan, Vereinigte Staaten, 48106
        • University of Michigan Medical Center
      • Detroit, Michigan, Vereinigte Staaten, 48202
        • Wayne State University
      • Southfield, Michigan, Vereinigte Staaten, 48075
        • St. John Providence Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Meet Fibromyalgia (FM) criteria of the American College of Rheumatology (ACR)either:

    • 1990 ACR criteria including tender points
    • 2010 ACR modified clinical criteria that does not include tender points

Exclusion Criteria:

  • Co-morbid autoimmune disorders, including rheumatoid arthritis and systemic lupus
  • Other serious medical conditions that can impair health status independent of FM
  • Current psychotic disorders (schizophrenia, bipolar disorder, etc.),dissociative identity (multiple personality) disorder, active suicide risk
  • Alcohol/drug dependence in past 2 years
  • Cognitive impairment or dementia
  • Currently have pending (or recently received - within 2 years) FM pain related disability or workman's compensation
  • Unable to fluently read or converse in English
  • Planning to move from the area in the next 14 months
  • Judgment of principle investigator as not appropriate for this trial or all intervention arms

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Stress and Emotions
Seeks to reduce stress and physical symptoms by helping individual become aware of their emotions, express them, and resolve emotional difficulties. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
Verhalten: Stress and Emotions
Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
Aktiver Komparator: Thoughts and Behaviors
Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms of fibromyalgia. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
Verhalten: Thoughts and Behaviors
Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
Aktiver Komparator: Brain and Body
Seeks to help individuals improve health by educating about fibromyalgia so that one can better understand and more effectively communicate about their health. It will explain the latest scientific information about fibromyalgia, including its causes, the role of the nervous system and body, various medical and alternative treatments, and how to understand research findings.
Verhalten: Brain and Body
Focus on the empowering patients by providing the latest scientific information about fibromyalgia, including causes, the role of the nervous system, and various treatments.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Zeitfenster
Brief Pain Inventory
Zeitfenster: Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Zeitfenster
SF-12
Zeitfenster: Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
PROMIS Fatigue short form
Zeitfenster: Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Pittsburgh Sleep Quality Index
Zeitfenster: Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Center for Epidemiological Studies - Depression Scale
Zeitfenster: Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Generalized Anxiety Disorder - 7
Zeitfenster: Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Positive and Negative Affect Schedule
Zeitfenster: Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Satisfaction with Life Scale
Zeitfenster: Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Multiple Ability Self-Report Questionnaire
Zeitfenster: Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Patient Global Assessment of Change
Zeitfenster: Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Health Care Utilization Scale
Zeitfenster: Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Baseline, post-treatment, 6 months post-treatment (primary endpoint), and 12 months post-treatment
Real-time Physical Activity (Actiwatch)
Zeitfenster: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
Heart Rate Variability
Zeitfenster: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
Levels of Emotional Awareness Scale
Zeitfenster: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
Emotional Expressivity Scale
Zeitfenster: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
Ambivalence over Emotional Expression
Zeitfenster: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
Toronto Alexithymia Scale-20
Zeitfenster: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
Impact of Events Scale - Revised
Zeitfenster: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
BBCA - short form
Zeitfenster: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
Pain Catastrophizing
Zeitfenster: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
Beliefs in Pain Control Questionnaire
Zeitfenster: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
Communication Thoughts and Feelings Questionnaire
Zeitfenster: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
Experimental (thumb nail pressure) threshold and tolerance ratings
Zeitfenster: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
2010 ACR modified clinical criteria for FM, including widespread pain index
Zeitfenster: Baseline, post-treatment, and 6 months post-treatment (primary endpoint)
Baseline, post-treatment, and 6 months post-treatment (primary endpoint)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Wayne State University

Mitarbeiter

University of Michigan
St. John Providence Hospital

Ermittler

  • Hauptermittler: Mark A Lumley, Ph.D., Wayne State University

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. Mai 2011

Primärer Abschluss (Tatsächlich)

1. Juli 2015

Studienabschluss (Tatsächlich)

1. Juli 2015

Studienanmeldedaten

Zuerst eingereicht

2. November 2010

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

28. Januar 2011

Zuerst gepostet (Schätzen)

1. Februar 2011

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Schätzen)

17. März 2016

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

15. März 2016

Zuletzt verifiziert

1. März 2016

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • 1R01AR057808 (US NIH Stipendium/Vertrag)

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Stress and Emotions

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Suriname

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

3
Abonnieren